<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181505</url>
  </required_header>
  <id_info>
    <org_study_id>06-78</org_study_id>
    <nct_id>NCT01181505</nct_id>
  </id_info>
  <brief_title>STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study</brief_title>
  <acronym>HNF4a</acronym>
  <official_title>STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to investigate the pharmacokinetics of tolterodine, substrate of CYP2D6 in
      healthy subject in relation to the presence of HNF-4A G60D variant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After a single oral administration of 2 mg tolterodine in 31 healthy subjects (6 with the
      heterozygous mutation of HNF-4A G60D vs 25 subjects with wild type of that whose CYP2D6
      genotype and gender were matched with variant group), blood were collected for 24hrs. Assay
      of tolterodine and the metabolite, 5-hyroxymethyl tolterodine was conducted using LC/MS/MS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, AUC, CL, Vd, T1/2</measure>
    <time_frame>24hr</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Genotype Guided(HNF4a)</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <arm_group_label>Tolterodine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject whose HNF4a and CYP2D6 genotype ware determined

        Exclusion Criteria:

          -  Subject whose HNF4a and CYP2D6 genotype ware not determined
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>August 12, 2010</last_update_submitted>
  <last_update_submitted_qc>August 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Department of Pharmacology and PharmacoGenomics Research Center</name_title>
    <organization>Inje University College of Medicine</organization>
  </responsible_party>
  <keyword>HNF4a</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>Toterodine</keyword>
  <keyword>Genetic polymorphism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

